Salus Therapeutics Overview

  • Founded
  • 1999

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $14.1M

Salus Therapeutics General Information

Description

Developer of drugs based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The company's drugs include antisense, small interfering RNAs and delivery systems for DNA/RNA-based drugs.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Genta
Primary Office
  • University Research Park
  • 615 Arapeen Drive, Suite 102
  • Salt Lake City, UT 84108
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Salus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-Aug-2003 $14.1M 00.00 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC 01-Jun-2003 00000 00.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 01-Jun-2002 00.00 00.00 Completed Generating Revenue
2. Early Stage VC (Series A) $1.2M Completed
1. Seed Round 01-Jul-1999 $1.2M Completed Startup
To view Salus Therapeutics’s complete valuation and funding history, request access »

Salus Therapeutics Patents

Salus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2003223619-A1 Antiviral phosphorothioate oligonucleotides Inactive 13-May-2002 00000000000

Salus Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EPIC Ventures Venture Capital Minority 000 0000 000000 0
Pelion Venture Partners Venture Capital Minority 000 0000 000000 0
Signal Peak Ventures Venture Capital Minority 000 0000 000000 0
To view Salus Therapeutics’s complete investors history, request access »